Received Mar 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC15 | PNEUMO (VAXNEUVANCE) | MERCK & CO. INC. | UNK | — | — |
| PPV | PNEUMO (PNEUMOVAX) | MERCK & CO. INC. | UNK | — | — |
splenectomy; This Spontaneous report was received from medical student (pharmacist intern) and referred to a 64 -year-old Male patient. The patient's medical history was not reported. The patient's past medications were not reported. The patient's concomitant medications were not reported. On 17-Nov-2022, the patient was vaccinated with a dose 15-Valent Pneumococcal Conjugate Vaccine (CRM197) Suspension for injection (VAXNEUVANCE) 0.5 mL (strength, dose number, route, lot #, expiration date and anatomical location were not provided) for prophylaxis. On 16-Aug-2014, the patient was vaccinated with a dose of Pneumococcal Vaccine, Polyvalent (23-valent) Solution for injection (PNEUMOVAX 23) 0.5 mL (strength, dose number, route, lot #, expiration date and anatomical location were not provided) for prophylaxis. On an unknown date, the patient experienced splenectomy. The Outcome of Splenectomy was not provided. It was mentioned that the primary reporter had an original objective referenced potential future Pneumococcal 21-valent Conjugate Vaccine Solution for injection (CAPVAXIVE) administration. The causal relationship between splenectomy with 15-Valent Pneumococcal Conjugate Vaccine (CRM197) Suspension for injection (VAXNEUVANCE) and Pneumococcal Vaccine, Polyvalent (23-valent) Solution for injection (PNEUMOVAX 23) was not provided. Upon internal review, the event splenectomy was determined to be Medically Significant.